Differential Reporting of In Situ Colorectal Cancer in New York State and the United States.
Surveillance of colorectal cancer (CRC) at all stages of diagnosis, including in situ, is necessary to have a complete picture of the patterns and trends of this disease. However, registry data suggest that the reporting of in situ CRC is variable. We used SaTScan statistical software to identify significant clusters of unusual CRC stage distribution in New York State (NYS) among cases diagnosed between 2010 and 2014. These results were compared to the CRC stage distribution within the National Program of Cancer Registries and Surveillance, Epidemiology, and End Results Program (SEER) 18 registries for the same period. We also computed rates and trends by type of reporting source (hospital inpatient vs outpatient surgery center), and reviewed the opinions of several NYS pathologists regarding the dividing line between in situ carcinoma and high-grade dysplasia (HGD). Seven areas within NYS were identified as having a statistically unusual proportion of in situ cases, ranging from 4% in Central New York to 22% on eastern Long Island. Nationally, the percentage ranged from 0.4% in the Seattle-Puget Sound SEER registry to 9.2% in Maryland. Feedback from clinicians revealed diverse opinions about the in situ/HGD boundary. In situ CRC is being reported inconsistently within New York and the United States, and lacks a universally agreed-upon definition. The recent downward trend in in situ CRC reported in the literature may be an artifact of changes in reporting practices.